Sue Wittich

24
Aug

Persica Pharmaceuticals Announces Collaboration with BackCare

Persica Pharmaceuticals Announces Collaboration with BackCare London, UK, 24 August 2022 – Persica Pharmaceuticals Ltd, a clinical stage pharmaceutical company developing a breakthrough injectable antibiotic formulation to treat patients suffering from chronic low back pain (CLBP), today announces a new collaboration with BackCare, a charity dedicated to back pain, regardless of cause. The two organisations share a goal to provide

Read more

24
Mar

Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons

Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons   London, UK, 24 March 2022 – Persica Pharmaceuticals Ltd, a clinical stage pharmaceutical company developing a breakthrough injectable antibiotic formulation, PP353, to treat patients suffering from chronic low back pain (CLBP), today announces that Peter Hamlyn, founding member and Non-Executive Director

Read more

3
Feb

European Patent Office has granted Persica’s first patent

European Patent Office has granted Persica’s first patent   London, UK, 03 February 2022 – Persica is delighted to announce that the European Patent Office has granted Persica’s first patent “Antibiotic Formulations for Lower Back Pain – EP3541442” which provides a foundation for our intellectual property. Persica’s novel antibiotic formulation for intradiscal administration of antibiotic to treat patients with Chronic Lower

Read more